Connect Biopharma reports new mechanism data for rademikibart drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St slips as Middle East uncertainty lifts oil; Trump-Xi talks in focus
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Plug Power COO resigns to join another company
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Wall Street ends down as oil prices, Treasury yields rise
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
January 12, 2026 8:00 AM ESTAnnounced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart
Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to further confirm its unique ability to rapidly improve airway function with topline results expected in first quarter 2026
Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in mid-2026
Strong balance sheet with cash runway into 2027 through key clinical catalysts
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma... More
